Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
This in-depth review examines the inherent challenges of providing cancer care for incarcerated patients.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen deprivation therapy in men with asymptomatic, nonmetastatic CRPC.
The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigational CD74-targeting antibody-drug conjugate STRO-001 for 2 blood cancers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer
- Expert Panel Provides Recommendations for Running Trials on Intratumoral Immunotherapy
- Large Acute Myeloid Leukemia Dataset Could Help Identify Targeted Treatments
- Treatment of H. pylori Increased Platelet Count in ITP
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD
- Prisoner or Patient? Challenges of Cancer Care in the Incarcerated Population